Recommended Free Tools
Align Technology (NASDAQ: ALGN) may look reasonably valued after its roughly 78% five-year share-price decline, but the fall alone does not make it cheap. The case depends on clear-aligner growth continuing, margins recovering, and future earnings or cash flow supporting the price. Align’s latest reported quarter, Q2 2026, showed growth in its aligner business but a decline in Imaging Systems and CAD/CAM Services revenue. That split makes ALGN a conditional valuation case—not an obvious bargain.
What Align Technology sells—and why the distinction matters
Align Technology designs, manufactures, and sells Invisalign clear aligners, iTero intraoral scanners, and exocad CAD/CAM software used in orthodontics and restorative dentistry. Its 2025 annual filing also lists related dental products such as retainers and cases, but the key investment distinction is between its clear-aligner business and its imaging systems and CAD/CAM services business.
Those businesses have recently moved in different directions. A rise in aligner revenue does not mean scanner and software revenue is also growing, and weakness in equipment sales does not by itself establish that aligner demand has weakened.
What Align reported in Q2 2026
In its July 29, 2026 earnings release, Align reported total Q2 revenue of $1,056.2 million, up 4.3% year over year. Clear aligners were the stronger segment: revenue was $870.9 million, up 8.2%, and case volume was 691.8 thousand, up 7.4%. By contrast, Imaging Systems and CAD/CAM Services revenue was $185.3 million, down 10.8% year over year.
The Tool Desk
Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →#1 Best Overall
| Measure | Q2 2026 result | What it indicates |
|---|---|---|
| Total revenue | $1,056.2 million; up 4.3% year over year (Align Technology, Q2 2026 release) | Overall growth, with different trends between the two reported business areas. |
| Clear Aligner revenue | $870.9 million; up 8.2% year over year (Align Technology, Q2 2026 release) | Growth in the treatment business during the quarter. |
| Clear-aligner cases | 691.8 thousand; up 7.4% year over year (Align Technology, Q2 2026 release) | Case volume also grew; revenue growth and case growth are distinct measures. |
| Imaging Systems and CAD/CAM Services revenue | $185.3 million; down 10.8% year over year (Align Technology, Q2 2026 release) | Equipment and related services were a source of weakness. |
Align attributed Imaging Systems and CAD/CAM Services softness to capital-equipment demand and a mix shift toward lower-priced scanners and more flexible acquisition models, including leases and rentals. Management also described expected double-digit year-over-year iTero scanner shipment growth for 2026. Shipment growth and revenue growth are not interchangeable: a shift toward less expensive equipment or flexible payment models can affect revenue even as shipments rise.
Profitability, cash, and capital returns
Align reported Q2 diluted GAAP EPS of $1.51 and non-GAAP diluted EPS of $2.64. These are different measures; the higher non-GAAP figure is not a substitute for GAAP earnings. The company said both were unfavorably affected year over year by about $0.23 because of foreign exchange.
At June 30, 2026, Align reported $1,102.6 million in cash and cash equivalents. It also repurchased about 0.4 million shares for approximately $67.0 million during Q2. Cash provides financial flexibility, and repurchases return capital to shareholders, but neither figure establishes what the shares are worth. To assess value, investors still need to consider the earnings or cash flows the business can generate over time and what they are paying for them.
Rank #2
- Ideal for Gifting
- Ideal for a bookworm
- Compact for travelling
What the 78% decline and valuation snapshots do—and do not—show
A September 2026 Yahoo Finance article described a roughly 78.0% five-year share-price decline. StockAnalysis reported an ALGN closing price of $143.74 on October 2, 2026. The percentage decline is a secondary-source historical description, while the close is a dated market-price observation; neither is a valuation conclusion.
Free tools Windows power users keep installed
One-click scans. No signup required.
A third-party valuation-ratios page showed a current trailing price-to-earnings ratio near 25 and a FY 2021 trailing P/E near 67. These are vendor snapshots, and the current snapshot’s observation date is not specified here. Trailing P/E depends on share price, the earnings period used, and vendor methodology. The two figures are not a clean comparison of what the stock should be worth today: they reflect different periods and do not account for what future earnings may be.
Yahoo Finance also presented a discounted-cash-flow estimate above the market price. That is a third-party model output, not an Align forecast or a verified fair value. A DCF result can change substantially with assumptions about growth, margins, cash generation, and the discount rate. No authoritative fair value is established by these snapshots.
The practical reading is limited but useful: a large fall can reset expectations, and the cited multiples are lower than the FY 2021 snapshot, but neither observation proves undervaluation. “Reasonable” is defensible only if an investor’s own assumptions about normalized future results support the price.
What would need to happen for ALGN to look reasonable?
Clear-aligner growth needs to hold up
Q2 2026 aligner revenue and case volume grew year over year. The thesis requires that growth to persist enough to support future sales and earnings; one quarter does not establish a durable trend. Investors can track subsequent reported case volumes and aligner revenue against this quarter’s baseline.
Do these 3 things before closing this tab:
1Scan for outdated or missing drivers - takes under a minute2Repair Windows errors before they cause bigger problems3Fix the driver behind crashes, sound loss and screen glitchesScanner economics need to work through the mix shift
Management described capital-equipment softness and a shift toward lower-priced scanners and flexible acquisition models. Those options may support adoption or the installed base, but the reported Q2 decline shows that scanner shipments alone cannot answer whether this business is contributing enough revenue and profit. Watch reported Imaging Systems and CAD/CAM Services revenue alongside shipment commentary.
Rank #4
Margins need to recover, not just revenue
Management forecast operating-margin improvement of approximately 100 basis points year over year in fiscal 2027. This is a forecast, not a reported result or guarantee. Align also expected one-time 2026 charges, including restructuring and accelerated depreciation. The valuation case is stronger if reported results subsequently show margin recovery while the business sustains growth; it weakens if charges, pricing pressure, or operating costs keep margins from improving.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Management’s outlook and the risks to the thesis
In its Q2 release, management described expectations for 2026 revenue and clear-aligner volume growth, as well as double-digit year-over-year iTero scanner shipment growth. It also expected a continued second-half mix shift toward lower-priced scanners and more flexible acquisition models. Management forecast approximately 100 basis points of year-over-year operating-margin improvement in fiscal 2027 and disclosed expected one-time charges in 2026, including restructuring and accelerated depreciation. These are forward-looking statements; they should be assessed against subsequent company results, not treated as achieved performance.
Align disclosed a UK tax matter in the same release. Following an Upper Tribunal determination that clear aligners do not qualify as VAT-exempt dental prostheses for invoices issued on or after September 7, 2026, the company estimated a liability of approximately $37.5 million, including interest, and said it intends to appeal. This is Align’s estimate and stated position, not a final determination of the amount owed or an independent legal conclusion.
Quick wins for a faster PC:
Repair Windows errors before they cause bigger problemsFix Now →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Clear out junk files and repair common Windows errorsFree Scan →Best Value
- It can be a gift option
- Comes with secure packaging
- Helpful in various ways
The principal ways the valuation thesis could disappoint include weaker-than-expected aligner demand or case growth, persistent scanner revenue or pricing pressure, failure to improve margins, and adverse foreign-exchange effects. Competition, customer economics, scanner adoption, and the outcome of the UK tax matter also merit monitoring. Align’s SEC filings provide fuller risk-factor context.
A practical way to judge the stock
- Set the date and price you are evaluating. The $143.74 figure is the StockAnalysis-reported close on October 2, 2026; later prices may differ.
- Use a consistent earnings or cash-flow period. Do not treat a vendor’s trailing P/E snapshot as a forecast or compare it uncritically with a multiple from another earnings period.
- Make the operating assumptions explicit. Estimate what sustained aligner growth, scanner economics, and margin recovery would mean for future earnings or cash flow. Separate your assumptions from Align’s management forecasts.
- Test a less favorable case. Consider what happens if aligner growth slows, equipment mix weighs on revenue, margins fail to improve, or foreign exchange and the tax matter create additional pressure.
- Compare the resulting value range with the market price. If the shares only appear attractive under optimistic assumptions, the 78% decline has not made the investment case robust.
The evidence available here does not support a precise fair-value target or a peer-ranking claim. The most supportable judgment is conditional: ALGN may be reasonable for an investor who believes future aligner growth and margin recovery can support the valuation, but the price decline itself is not evidence that it is undervalued.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
